Principles for modulation of the nuclear receptor superfamily

Nature Reviews Drug Discovery

Volumn 3, Issue 11, 2004, Pages 950-964

  Gronemeyer, Hinrich ^a   Gustafsson, Jan Åke ^b   Laudet, Vincent ^c  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALITRETINOIN; ANDROGEN RECEPTOR; BEXAROTENE; CELL NUCLEUS RECEPTOR; DEXAMETHASONE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN RECEPTOR; FARNESOID X RECEPTOR; GLUCOCORTICOID RECEPTOR; LIGAND; LIVER X RECEPTOR; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PONASTERONE A; PREGNANE X RECEPTOR; PROGESTERONE RECEPTOR; RALOXIFENE; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TAMOXIFEN; THYROID HORMONE; THYROID HORMONE RECEPTOR; UNINDEXED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

BONE CANCER; BREAST CANCER; CELL TYPE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FAMILY; RETROSPECTIVE STUDY; REVIEW;

BINDING SITES; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8844262660     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1551     Document Type: Review

References (116)

1. Laudet, V. & Gronemeyer, H. The Nuclear Receptors Factbooks (Academic, San Diego, 2001).
2. Gehin, M. et al. Structural basis for engineering of retinoic acid receptor isotype-seleGtive agonists and antagonists. Chem. Biol. 6, 519-529 (1999).
3. Germain, P., Iyer, J., Zechel, C. & Gronemeyer, H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415, 187-192 (2002).
4. Chen, J. Y. et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14, 1187-1197 (1995).
5. Coghlan, M. J. et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol. Endocrinol. 17, 860-869 (2003).
6. Herrlich, P. Cross-talk between glucocorticoid receptor and AP-1. Oncogene 20, 2465-2475 (2001).
7. Jordan, V. C. Antioestrogens and selective oestrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem. 46, 863-908 (2003).
8. Jordan, V. C. Antioestrogens and selective oestrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 46, 1081-1111 (2003).
9. Shang, Y. & Brown, M. Molecular determhants for the tissue specificity of SERMs. Science 295, 2465-2468 (2002).
10. Hafezi-Moghadam, A. et al. Acute cardiovascular protective effects of corticosteroids are mediated by nontranscriptional activation of endothelial nitric oxide synthase. Nature Med. 8 473-479 (2002).
11. Simoncini, T. et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538-541 (2000).
12. Kumar, R. et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm. Nature 418 654-657 (2002).
13. Altucci, L. et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligard TRAIL. Nature Med. 7, 680-686 (2001).
14. Wrange, Ö. & Gustafsson J.-Å. Separation of the hormone-and DNA-binding sites of the hepatic glucocorticoid receptor by means of proteolysis. J. Biol. Chem. 253, 856-865 (1978).
15. Bourguet, W., Germain, P. & Gronemeyer, H. Nuclear receptor ligand-binding domains: 3D structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21, 381-388 (2000).
16. Wurtz, J. M. et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nature Struct. Biol. 3, 87-94 (19996)
17. He, B. et al. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J. Biol. Chem. 277, 25631-25639 (2002).
18. Glass, C. K. & Rosenfeld, M. G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14 121-141 (2000).
19. McKenna, N. J., Lanz, R. B. & O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocrine Rev. 20, 321-344 (1999).
20. Métivier, R. et al. Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115, 751-763 (2003).
21. Laudet, V, Hänni, C., Coll, J., Catzeflis, F. & Stéhelin, D. Evolution of the nuclear receptor superfamily. EMBO J. 11, 1003-1013 (1992).
22. Escriva, H., Bertrand, S. & Laudet, V. The evolution of the nuclear receptor superfamily. Essays Biochem. 40, 11-26 (2004).
23. Kuiper, G. G., Enmark, E, Pelto-Huikko, M., Nilsson, S. & Gustafsson, J.-Å. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 93, 5925-5230 (1996).
24. Gustafsson, J.-Å. What pharmacologists can learn from recent advances in oestrogen signaling. Trends Pharmacol. Sci. 24, 479-485, (2003).
25. Katzenellenbogen, B. S. et al. Structure-function relationships in oestrogen receptors and the characterization of novel selective oestrogen receptor modulators with unique pharmacological profiles. Ann. NY Acad. Sci. 949, 6-15 (2001).
26. Matt, N., Ghyselinck, N. B., Wendling, O., Chambon, P. & Mark, M. Retinoic acid-induced developmental defects are mediated by RARβ/RXR reterodimers in the pharyngeal endoderm. Development 130, 2083-2093 (2003).
27. Massaro, G. D., Massaro, D. & Chambon, P. Retinoic acid receptor-α regulates pulmonary alveolus formation in mice after, but not during, perinatal perod. Am. J. Physiol. Lung Cell. Mol. Physiol. 284, L431 -L433 (2003).
28. Chiang, M. Y. et al. An essential role for retinoid receptors RARβ and RXRγ in long-term potentiation and depression. Neuron 21, 1353-1361 (1998).
29. Kastner, P. et al. Positive and negative regulation of granulopoiesis by endogenous RARα. Blood 97, 1314-1320 (2001).
30. Li, M. et al. Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis. Nature 407, 633-636 (2000).
31. Zusi, F. C., Lorenzi, M. V. & Vivat-Hannah, V. Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov. Today 7, 1165-1174 (2002).
32. Chen, J. Y. et al. Two distinct actions of retinoid-receptor ligands. Nature 382, 819-822 (1996).
33. Nagy, L. et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol. Cell. Biol. 15, 3540-3551 (1995).
34. Renaud, J. P. et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378, 681-689 (1995).
35. Kaholz, B. P., Mitschler, A. & Moras, D. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J. Mol. Biol. 302, 155-170 (2000).
36. Klaholz, B. P. et al. Conformational adaptation of agonists to the human nuclear receptor RAR-γ. Nature Struct. Biol. 5, 199-202 (1998).
37. Billas, I. M. L. et al. Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor. Nature 426, 91-96 (2003).
38. Färnegarch, M. et al. The three-dimensional structure of the liver X receptor-β reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J. Biol. Chem. 278, 38821-38828 (2003)
39. Peach, K. et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277, 1508-1510 (1997).
40. Berry, M., Metzger, D. & Chambon, P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9, 2811-2818 (1990).
41. Kushner, P. J., et al. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74, 311-317 (2000).
42. Saville, B, et al. Ligand-, cell-, and estrogen receptor subtype (α/β)-clependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem. 275, 5379-5387 (2000).
43. Liu, M. M. et al. Opposing action of estrogen receptors α and β on cyclin D1 gene expression. J. Biol. Chem. 277, 24353-24360 (2002).
44. Chen, H., Tini, M. & Evans, R. M. HATs on and beyond chromatin. Curr. Opin. Cell. Biol. 13, 218-224 (2001).
45. Shang, Y., Hu, X., Di Renzo, J., Lazar, M. A. & Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843-852 (2000).
46. Ikura, T. et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 102, 463-473 (2000).
47. Katzenellenbogen, B. S. & Katzenellenbogen J. A. Defining the 'S' in SERMs. Science 295, 2380-2381 (2002).
48. Bocquel, M. T., Kumar, V., Stricker, C., Chambon, P. & Gronemeyer, H. The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. Nucleic Acids Res. 17, 2581-2595 (1989).
49. Sporn, M. B., Suh, N. & Mangelsdorf, D. J. Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs). Trends Mol. Med. 7, 395-400 (2001).
50. Negro-Vilar, A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. 84, 3459-3462 (1999).
51. Giannoukos, G., Szapary, D., Smith, C. L., Meeker, J. E. & Simons, S. S. New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties. Mol. Endocrinol. 15, 255-270 (2001).
52. Rocchi et al. A unique PRARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8 737-747 (2001).
53. Olive D. L. Role of progesterone antagonists and new selective progesterone receptor modulators in reproductive health. Obstet. Gynecol. Surv. 57, S55-S63 (2002).
54. Brower, V. A second chance for hormone replacement therapy? EMBO Rep. 4, 1112-1115 (2003).
55. de Urquiza, A. M. et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290, 2140-2144 (2000).
56. Kurokawa, R. et al. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature 371, 528-531 (1994).
57. Chen, Z. et al. Ligand- and DNA-induced dissociation of RXR tetramers. J. Mol. Biol. 275, 55-65 (1998).
58. Kersten, S., Dawson, M. I., Lewis, B. A. & Noy, N. Individual subunits of heterodimers comprised of retinoic acid and retinoid X receptors interact with their ligands independently. Biochemistry 35, 3816-3824 (1996).
59. Minucci, S. et al. Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid-dependent gene expression. Mol. Cell. Biol. 17, 644-655 (1997).
60. Altucci, L. & Gronemeyer, H. The promise of retinoids to fight against cancer. Nature Rev. Cancer 1, 181-193 (2001).
61. Germain, P. et al. Rational design of RAR selective ligands revealed by RARβ crystal structure. EMBO Rep. 5, 877-882 (2004).
62. Blumberg, B. & Evans, R. M. Orphan nuclear receptors-new ligands and new possibilities. Genes Dev. 12, 3149-3155 (1998).
63. Wiebel, F. F., Steffensen, K. R., Treuter E., Feltkamp D. & Gustafsson J.-Å. Ligand-independent coregulator recruitment by the triply activatable OR1/Retinoid X receptor-α nuclear receptor heterodimer. Mol. Endocrinol. 13, 1105-1118, (1999).
64. Esteva, F. J. et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J. Clin. Oncol. 21, 999-1006 (2003).
65. Mukherjee, R. et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407-410 (1997).
66. Michellys, P. Y. et al. Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes. J. Med. Chem. 46, 2683-2696 (2003).
67. Duvic, M. et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J. Clin. Oncol. 19, 2456-2471 (2001).
68. Krathen, R. A., Ward, S. & Duvic, M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 206, 142-147 (2003).
69. Aboulafia D. M. et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch. Dermatol. 139, 178-186 (2003)
70. Benoit, G. et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18, 7011-7018 (1999).
71. Dawson, M. I. Synthetic retinoids and their nuclear receptors. Curr. Med. Chem. Anti-Canc. Agents 4, 199-230 (2004).
72. Hong, W. K. & Sporn, M. B. Recent advances in chemoprevention of cancer. Science 278, 1073-1077 (1997).
73. Sudbo, J. et al. Molecular based treatment of oral cancer. Oral Oncol. 39, 749-758 (2003).
74. Sun, S. Y. & Lotan, R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol. 41, 41-55 (2002).
75. Shin, D. M. et al. Accumulation of p53 protein and retinoic acid receptor-β in retinoid chemoprevention. Clin. Cancer Res. 3, 875-880 (1997).
76. Kurie, J. M. et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-β expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J. Natl Cancer Inst. 95, 206-214 (2003).
77. Clarke, N. et al. Tumor suppressor IRF1 mediates retinoid and interferon anti-cancer signalling to death ligand TRAIL. EMBO J. 23, 3051-3060 (2004).
78. Giguere, V., Yang, N., Segui, P. & Evans, R. M. Identification of a new class of steroid hormone receptors. Nature 331, 91-94 (1988).
79. Tremblay, G. B. et al. Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERRβ. Genes Dev. 15, 833-888 (2001).
80. Coward, P., Lee, D., Hull, M. V. & Lehmann, J. M. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor-γ. Proc. Natl Acad. Sci. USA 98, 8880-8884 (2001).
81. Horard, B. & Vanacker J.-M. ERRs: orphan receptors desperately seeking ligand. J. Mol. Endocrinol. 31, 349-357 (2003).
82. Vanacker, J. M., Pettersson, K., Gustafsson, J.-Å. & Laudet, V. Transcriptional targets shared by estrogen-receptor related receptors (ERRs) and estrogen receptors (ER)α but not by ERβ. EMBO J. 18, 4270-4279 (1999).
83. Bonnelye, E. et al. The ERR-1 orphan receptor is a transcriptional activator expressed during bone formation. Mol. Endocrinol. 11, 905-916 (1997).
84. Bonnelye, E. & Aubin, J. E. Differential expression of estrogen receptor-related receptor-α and estrogen receptors α and β in osteoblasts in vivo and in vitro. J. Bone Miner. Res. 17 1392-1400 (2002).
85. Chawla, A., Repa, J. J., Evans, R. M. & Mangelsdort, D. J. Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001).
86. Lee, C. H., Olson, P. & Evans, R. M. Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144, 2201-2207 (2003).
87. Solomin, L. et al. Retinoid-X receptor signalling in the developing spinal cord. Nature 395, 398-402 (1998).
88. Conneely, O. M., Mulac-Jericevic, B., Lydon, J. P. & de Mayo, F. J. Reproductive functions of the progesterone receptor isoforms: lessons from knock out mice. Mol. Cell. Endocrinol. 179, 97-103 (2001).
89. Kliewer, S. A. et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92, 73-82 (1998).
90. Dotzlaw, H., Leygue, E., Watson, P. & Murphy, L. C. The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin. Cancer Res. 6, 2103-2107 (1999).
91. De Bosscher, K., Vanden Berghe, W. & Haegeman, G. Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators. Mol. Endocrinol. 15, 219-227 (2001).
92. Kassel, O. et al. A nuclear isoform of the focal adhesion LIM domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-κB-regulated promoters. Genes Dev. 18 2518-2528 (2004).
93. Reichardt, H. M., Tronche, F., Berger, S., Kellendonk, C. & Schutz, G. New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv. Pharmacol. 47, 1-21 (2000).
94. Vayssiere, B. M. et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 11, 1245-1255 (1997).
95. Van den Berghe, W., Francesconi, E., De Bosscher, K., Resche-Rigon, M. & Haegeman, G. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-κB-dependent mechanism. Mol. Pharmacol. 56, 797-806 (1999).
96. Fu, M. et al. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol. Cell. Biol. 22, 3373-3388 (2002).
97. Wang, C. et al. Direct acetylation of the oestrogen receptor-α hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276, 18375-18383 (2001 ).
98. Couse, J. F. & Korach, K. S. Oestrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20, 358-417 (1999).
99. Michalides, R. et al. Tamoxiffen resistance by a conformational arrest of the estrogen receptor a after PKA activation in breast cancer. Cancer Cell 5, 597-605 (2004).
100. Chambliss, K. L. & Shaul, P. W. Oestrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 23, 665-686 (2002).
101. Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the oestrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719-730 (2001).
102. Stehlin-Gaon, C. et al. All-trans retinoic acid is a ligand for the orphan nuclear receptor RORβ. Nature Struct. Biol. 10, 820-825 (2003).
103. Shaw, N., Elholm, M. & Noy, N. Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptorβ/δ. J. Biol. Chem. 278, 41580-41592 (2003).
104. Escriva, H. et al. Ligand binding was acquired during evolution of nuclear receptors. Proc. Natl Acad. Sci. USA 94, 6803-6808 (1997).
105. Grasso, L. C. et al. The evolution of nuclear receptors: evidence from the coral Acropora. Mol. Phylogenet. Evol. 21, 93-102 (2001).
106. Kostrouch, Z. et al. Retinoic acid X receptor in the diploblast, Tripedalia cystophora. Proc. Natl Acad. Sci. USA 95 13442-13447 (1998).
107. Wiens, M., Batel, R., Korzhev, M. & Muller, W. E. Retinoid X receptor and retinoic acid response in the marine sponge Suberites domuncula. J. Exp. Biol. 206, 3261-3271 (2003).
108. Thornton, J. W., Need, E. & Crews, D. Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. Science 301, 1714-1717 (2003).
109. Ohtake, F. et al. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423, 545-550 (2003).
110. Norris, J. D. et al. Peptide antagonists of the human estrogen receptor. Science 285, 744-746 (1999).
111. Ferrara, F. F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2-7 (2001).
112. Nuclear Receptor Nomenclature Committee. A unified nomenclature system for the nuclear receptors superfamily. Cell 97, 161-163 (1999).
113. Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal. 15, 355-366 (2003).
114. Bertrand, S. et al. Evolutionary genomics of nuclear receptors: from 25 ancestral genes to derived endocrine systems Mol. Biol. Evol. 21, 1923-1937 (2004).
115. Elger, W. et al. International patent application WO-03045396.
116. Robinson-Rechavi, M. Escriva-Garcia, H. & Laudet, V. The nuclear receptor superfamily. J. Cell Sci. 116, 585-586 (2003).